Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy. The results would be used to determine dosing for further evaluation in phase 2 clinical testing.
“First-in-human phase 1 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer”
The poster, entitled, "First-in-human phase 1 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer" will be presented on Monday, June 7 from 8:00 a.m. to 12:00 p.m. Central Time. The "Trials in Progress" Poster Session is designed to facilitate communication among current and potential investigators about ongoing clinical trials and provides background of the science behind an ongoing trial highlighting trial design and enrollment of subjects (outcomes data or results are prohibited from presentation).
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy